checkAd

     192  0 Kommentare Ziopharm Oncology Completes Enrollment of Phase 2 Trial Evaluating Controlled IL-12 in Combination with Libtayo in Patients with Glioblastoma - Seite 3

    Investor Relations Contacts:
    Ziopharm Oncology:
    Chris Taylor
    VP, Investor Relations and Corporate Communications
    T: 617.502.1881
    E: ctaylor@ziopharm.com

    LifeSci Advisors:
    Mike Moyer
    Managing Director
    T: 617.308.4306
    E: mmoyer@lifesciadvisors.com

    Lesen Sie auch

    Media Relations Contact:
    LifeSci Communications:
    Patrick Bursey
    T: 646.876.4932
    E: pbursey@lifescicomms.com


    Diskutieren Sie über die enthaltenen Werte


    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Ziopharm Oncology Completes Enrollment of Phase 2 Trial Evaluating Controlled IL-12 in Combination with Libtayo in Patients with Glioblastoma - Seite 3 BOSTON, June 22, 2020 (GLOBE NEWSWIRE) - Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced that 36 subjects have been enrolled in the phase 2 clinical trial evaluating Ad-RTS-hIL-12 with veledimex (Controlled …